Boehringer Ingelheim will exhibit at the 2019 International Producing and Processing Expo (IPPE), the world's largest poultry exhibition held in Atlanta, GA, USA, with its vector vaccines Vaxxitek^® HVT + IBD and Newxxitek® HVT + ND.

Vaxxitek^® HVT + IBD

Vaxxitek^® HVT + IBD protects against two major immunosuppressive diseases: Infectious Bursal Disease (IBD) and Marek's disease (MD). In October 2018, Boehringer Ingelheim celebrated a milestone of over 100 billion birds vaccinated with VAXXITEK^® HVT + IBD worldwide since its launch in 2006.

To date, Vaxxitek^® HVT + IBD is registered in more than 75 countries. It was launched in 2006 in Brazil and since then, in Europe, Middle East, Africa and China.

Newxxitek^® HVT + ND

Newxxitek, the latest vectored Newcastle disease technology produced by Boehringer Ingelheim, protects flocks against Newcastle disease, even velogenic strains with no adverse reaction post-vaccination.

Newxxitek^® HVT + ND was launched in 2018 in velogenic Newcastle areas such as Peru, Egypt, Philippines and Thailand.

“Over the world, our hatchery vector vaccines help simplify the vaccination programme and contribute significantly to improve the live production performance of poultry producers,” said Jerome Baudon, Head of Poultry Strategic Business Unit at Boehringer Ingelheim.

The Boehringer Ingelheim team will be pleased to welcome you at our booth (C10623) in Hall C and Lobby C.

Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.